Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05295407 · ClinicalTrials.gov registry record
Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy
A clinical trial of Prostate Cancer, sponsored by Endeavor Health.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 1
- Study location
NCT05295407: Recruiting study of Prostate Cancer, sponsored by Endeavor Health.
NCT05295407 is a study of Prostate Cancer that is actively recruiting participants, run by Endeavor Health. The registered enrollment target is 1,000 participants, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (65% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05295407, a study of Prostate Cancer, is actively recruiting participants, sponsored by Endeavor Health.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
Condition: Prostate cancer Intervention: Biopsy and inherited risk assessment
Primary Outcome
The primary outcome measure is prostate cancer diagnosis from the prostate biopsy report. The primary goal is to compare prostate cancer detection rate in patients of three inherited risk groups (high-risk, intermediate-risk, and low-risk).
Conditions Studied
Interventions
- GENETIC Genetic Assessment
Study Locations (1)
Illinois
- NorthShore University HealthSystem - Evanston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2021-12-13 |
| Est. Completion | 2027-12-13 |
What NCT05295407 shows while recruiting
NCT05295407 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (65% higher).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Genetic Assessment is the first listed.
NCT05295407 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT05295407 about?
NCT05295407 is a clinical study titled "Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy". Condition: Prostate cancer Intervention: Biopsy and inherited risk assessment
What is the current status of trial NCT05295407?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2021-12-13. Estimated completion is 2027-12-13.
What conditions does trial NCT05295407 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT05295407?
The interventions under investigation include: Genetic Assessment (GENETIC).
Who is sponsoring clinical trial NCT05295407?
This trial is sponsored by Endeavor Health, which has 94 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05295407 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05295407's enrollment target sits among peer trials
1,000 59th of 735 higher than 669 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI